logo-loader
viewLexaria Bioscience Corp.

Full interview: Lexaria BioScience CEO releases letter to shareholders as company looks for big 2020

Lexaria BioScience (CSE:LXX-OTCQX: LXRP) CEO Chris Bunka joined Steve Darling from Proactive on Skype to discuss his letter to shareholders to start 2020. Bunka talked about some of the things he addressed in the letter including success in 2019 and what is head in 2020.

Bunka also talked about the capital markets and what he sees as an optional path for Lexaria in 2020. 
 

Quick facts: Lexaria Bioscience Corp.

Price: 0.52 CAD

CSE:LXX
Market: CSE
Market Cap: $46.59 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Lexaria Bio Science and partner Altria complete Phase One of the development...

Lexaria BioScience (OTCQX: LXRP- CSE: LXX) CEO Chris Bunka joined Steve Darling from Proactive Vancouver with news the company has seen their Phase One research and development program of oral forms of nicotine delivery finish with Altria Ventures. Bunka says everything went as planned and...

2 weeks, 6 days ago

2 min read